Article
Cystic fibrosis year in review 2020: Section 2 pulmonary disease, infections, and inflammation.
Pediatric pulmonology - 1 Feb 2022
Antos Nicholas J, Savant Adrienne P
Abstract excerpt
The outlook for those with cystic fibrosis (CF) has never been brighter with ever increasing life expectancy and the approval of the highly effective CFTR modulators, such as elexacaftor/tezacaftor/ivacaftor. With that being said, the progressive pulmonary decline and importance of lung health, infection, and inflammation in CF remains. This review is the second part in a three-part CF Year in Review 2020. Part...
Topics
Join the communities discussing this publication.